NEW YORK, May 31, 2024--Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). After five years of median follow-up, median progression-free survival (PFS) based on investigator asses
Moderna stock seesawed Thursday after confirming the U.S. government is nearing a deal to fund its pandemic bird flu vaccine.
Pfizer stock is now above its 50-day line on better-than-expected first-quarter sales. Is PFE stock a buy now?